WO2002006214A1 - Derives a l'acide sulfonique d'acides hydroxamiques et leur utilisation comme produits medicaux - Google Patents
Derives a l'acide sulfonique d'acides hydroxamiques et leur utilisation comme produits medicaux Download PDFInfo
- Publication number
- WO2002006214A1 WO2002006214A1 PCT/JP2001/006275 JP0106275W WO0206214A1 WO 2002006214 A1 WO2002006214 A1 WO 2002006214A1 JP 0106275 W JP0106275 W JP 0106275W WO 0206214 A1 WO0206214 A1 WO 0206214A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- methyl
- phenyl
- ethylcarbamoyl
- alkyl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 160
- 150000003458 sulfonic acid derivatives Chemical class 0.000 title claims abstract description 97
- 150000007513 acids Chemical class 0.000 title abstract description 5
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 65
- 239000003112 inhibitor Substances 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 219
- -1 cyano, nitro, amino Chemical group 0.000 claims description 180
- 125000000217 alkyl group Chemical group 0.000 claims description 117
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 66
- 239000001257 hydrogen Substances 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 229910052757 nitrogen Inorganic materials 0.000 claims description 47
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 44
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 125000006239 protecting group Chemical group 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
- FWPKDESKJMMUSR-UHFFFAOYSA-N n-hydroxyhexanamide Chemical compound CCCCCC(=O)NO FWPKDESKJMMUSR-UHFFFAOYSA-N 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 239000011630 iodine Substances 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 6
- 125000004957 naphthylene group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 abstract description 35
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 30
- 239000000543 intermediate Substances 0.000 abstract description 22
- 238000003786 synthesis reaction Methods 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
- 238000000034 method Methods 0.000 description 82
- 239000000243 solution Substances 0.000 description 73
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- 238000006243 chemical reaction Methods 0.000 description 56
- 150000001412 amines Chemical class 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- 239000000203 mixture Substances 0.000 description 46
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 41
- 159000000000 sodium salts Chemical class 0.000 description 37
- 239000002244 precipitate Substances 0.000 description 36
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 35
- 239000002904 solvent Substances 0.000 description 34
- 230000008569 process Effects 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 238000001914 filtration Methods 0.000 description 27
- 150000002431 hydrogen Chemical class 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000001816 cooling Methods 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 150000003443 succinic acid derivatives Chemical class 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 238000010792 warming Methods 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 125000004043 oxo group Chemical group O=* 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 125000005931 tert-butyloxycarbonyl group Chemical class [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 239000000010 aprotic solvent Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 6
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical class C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000004210 ether based solvent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- OBESRABRARNZJB-UHFFFAOYSA-N aminomethanesulfonic acid Chemical compound NCS(O)(=O)=O OBESRABRARNZJB-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 238000010531 catalytic reduction reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical class O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- PXZHWADUPLBMFL-UHFFFAOYSA-N sodium N-oxidohexanamide Chemical compound [Na+].CCCCCC(=O)N[O-] PXZHWADUPLBMFL-UHFFFAOYSA-N 0.000 description 3
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 150000008053 sultones Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- FSSPGSAQUIYDCN-UHFFFAOYSA-N 1,3-Propane sultone Chemical compound O=S1(=O)CCCO1 FSSPGSAQUIYDCN-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- IVFRNNGYRFSLNH-BQFBZIMZSA-M CCCC[C@H](C(N[C@@H](CC1=CC=CC=C1)C(NCS([O-])(=O)=O)=O)=O)C(N[O-])=O.[Na+].[Na+] Chemical compound CCCC[C@H](C(N[C@@H](CC1=CC=CC=C1)C(NCS([O-])(=O)=O)=O)=O)C(N[O-])=O.[Na+].[Na+] IVFRNNGYRFSLNH-BQFBZIMZSA-M 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000005456 alcohol based solvent Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001356 alkyl thiols Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000005604 azodicarboxylate group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003759 ester based solvent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000002443 hydroxylamines Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229950000244 sulfanilic acid Drugs 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003459 sulfonic acid esters Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VRKUNXWBGNYJQG-SECBINFHSA-N (2r)-2-amino-3-(4-hydroxyphenyl)-n-methylpropanamide Chemical compound CNC(=O)[C@H](N)CC1=CC=C(O)C=C1 VRKUNXWBGNYJQG-SECBINFHSA-N 0.000 description 1
- TXOXCTZAXYALHN-SBSPUUFOSA-N (2r)-2-amino-3-(4-hydroxyphenyl)-n-methylpropanamide;hydrochloride Chemical compound Cl.CNC(=O)[C@H](N)CC1=CC=C(O)C=C1 TXOXCTZAXYALHN-SBSPUUFOSA-N 0.000 description 1
- CNBUSIJNWNXLQQ-LLVKDONJSA-N (2r)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-LLVKDONJSA-N 0.000 description 1
- BWBHIIJKOYBHON-YFKPBYRVSA-N (2s)-2-(2-carboxyethylamino)pentanedioic acid Chemical compound OC(=O)CCN[C@H](C(O)=O)CCC(O)=O BWBHIIJKOYBHON-YFKPBYRVSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- VRKUNXWBGNYJQG-VIFPVBQESA-N (2s)-2-amino-3-(4-hydroxyphenyl)-n-methylpropanamide Chemical compound CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VRKUNXWBGNYJQG-VIFPVBQESA-N 0.000 description 1
- TXOXCTZAXYALHN-FVGYRXGTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)-n-methylpropanamide;hydrochloride Chemical compound Cl.CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 TXOXCTZAXYALHN-FVGYRXGTSA-N 0.000 description 1
- LYFJTHSAYJYOMC-UQKRIMTDSA-N (2s)-2-amino-3-(4-hydroxyphenyl)-n-phenylpropanamide;hydrochloride Chemical compound Cl.C([C@H](N)C(=O)NC=1C=CC=CC=1)C1=CC=C(O)C=C1 LYFJTHSAYJYOMC-UQKRIMTDSA-N 0.000 description 1
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 1
- PACOJMUEMCYUBQ-VKHMYHEASA-N (3S)-3-amino-4-(carboxymethoxy)-4-oxobutanoic acid Chemical compound OC(=O)C[C@H](N)C(=O)OCC(O)=O PACOJMUEMCYUBQ-VKHMYHEASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WXUAQHNMJWJLTG-VKHMYHEASA-N (S)-methylsuccinic acid Chemical compound OC(=O)[C@@H](C)CC(O)=O WXUAQHNMJWJLTG-VKHMYHEASA-N 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- DDBVMIMQIZGFBZ-WTQRLHSKSA-N 1-o,2-o-dibenzyl 1-o-tert-butyl (2r)-4-methylpentane-1,1,2-tricarboxylate Chemical compound CC(C)(C)OC(=O)C([C@@H](CC(C)C)C(=O)OCC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 DDBVMIMQIZGFBZ-WTQRLHSKSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- YJYAGNPMQVHYAH-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethanol Chemical compound CC(C)(C)[Si](C)(C)OCCO YJYAGNPMQVHYAH-UHFFFAOYSA-N 0.000 description 1
- OHHXFBMIZJDKRS-UHFFFAOYSA-N 2-amino-2-butylheptanoic acid Chemical compound CCCCCC(N)(C(O)=O)CCCC OHHXFBMIZJDKRS-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- QVQDALFNSIKMBH-UHFFFAOYSA-N 2-pentoxyethanol Chemical compound CCCCCOCCO QVQDALFNSIKMBH-UHFFFAOYSA-N 0.000 description 1
- CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- KFJDQPJLANOOOB-UHFFFAOYSA-N 2h-benzotriazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=NNN=C12 KFJDQPJLANOOOB-UHFFFAOYSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- FUCYABRIJPUVAT-UHFFFAOYSA-N 3-phenylmethoxypropan-1-ol Chemical compound OCCCOCC1=CC=CC=C1 FUCYABRIJPUVAT-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KNILZINKISHVIQ-UHFFFAOYSA-N 4-azaniumylbutane-1-sulfonate Chemical compound NCCCCS(O)(=O)=O KNILZINKISHVIQ-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- TYROJDFHUXSBHC-UHFFFAOYSA-N 4-phenylmethoxybutan-1-ol Chemical compound OCCCCOCC1=CC=CC=C1 TYROJDFHUXSBHC-UHFFFAOYSA-N 0.000 description 1
- NJVWBSNUDITJDJ-UHFFFAOYSA-N 5-aminopentane-1-sulfonic acid Chemical compound NCCCCCS(O)(=O)=O NJVWBSNUDITJDJ-UHFFFAOYSA-N 0.000 description 1
- LPNANKDXVBMDKE-UHFFFAOYSA-N 5-bromopent-1-ene Chemical compound BrCCCC=C LPNANKDXVBMDKE-UHFFFAOYSA-N 0.000 description 1
- RZVDPWSEPVHOPU-UHFFFAOYSA-N 5-phenylmethoxypentan-1-ol Chemical compound OCCCCCOCC1=CC=CC=C1 RZVDPWSEPVHOPU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- DSUVWPBXIAKHJU-UHFFFAOYSA-N C(C)(C)C(CC)(N=C=N)C(C)C Chemical compound C(C)(C)C(CC)(N=C=N)C(C)C DSUVWPBXIAKHJU-UHFFFAOYSA-N 0.000 description 1
- STDADVNDUXKPPH-UHFFFAOYSA-N C1=C(C=CC2=CC=CC=C12)CC(C(=O)NO)CCCC Chemical compound C1=C(C=CC2=CC=CC=C12)CC(C(=O)NO)CCCC STDADVNDUXKPPH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000277306 Esocidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101150102885 RGR1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 241000051616 Ulmus minor Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- JPONAEJXLMLEKR-UHFFFAOYSA-L [OH-].[Na+].[O-]P(O)(=O)OP(=O)(O)O.[Na+] Chemical compound [OH-].[Na+].[O-]P(O)(=O)OP(=O)(O)O.[Na+] JPONAEJXLMLEKR-UHFFFAOYSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- CEXFHIYDTRNBJD-RSAXXLAASA-N benzyl (2s)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 CEXFHIYDTRNBJD-RSAXXLAASA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- UXXXZMDJQLPQPH-UHFFFAOYSA-N bis(2-methylpropyl) carbonate Chemical compound CC(C)COC(=O)OCC(C)C UXXXZMDJQLPQPH-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- OZXMJFAYFGJFNF-UHFFFAOYSA-N cesium;methylazanide Chemical compound [Cs+].[NH-]C OZXMJFAYFGJFNF-UHFFFAOYSA-N 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- SYZWSSNHPZXGML-UHFFFAOYSA-N dichloromethane;oxolane Chemical compound ClCCl.C1CCOC1 SYZWSSNHPZXGML-UHFFFAOYSA-N 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 1
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- OHMBHFSEKCCCBW-UHFFFAOYSA-N hexane-2,5-diol Chemical compound CC(O)CCC(C)O OHMBHFSEKCCCBW-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 125000006352 iso-propylthiomethyl group Chemical group [H]C([H])([H])C([H])(SC([H])([H])*)C([H])([H])[H] 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- CDAWCLOXVUBKRW-UHFFFAOYSA-N ortho-hydroxyaniline Natural products NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- MHYFEEDKONKGEB-UHFFFAOYSA-N oxathiane 2,2-dioxide Chemical compound O=S1(=O)CCCCO1 MHYFEEDKONKGEB-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- RYTRESGBLJPGDE-UHFFFAOYSA-M sodium;5-bromopentane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCCCCBr RYTRESGBLJPGDE-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
- C07C309/09—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing etherified hydroxy groups bound to the carbon skeleton
- C07C309/11—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing etherified hydroxy groups bound to the carbon skeleton with the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
- C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
Definitions
- the present invention relates to a novel hydroxamic acid-based sulfonic acid derivative or a chemically acceptable salt thereof. More specifically, it relates to a hydroxamic acid-based sulfonic acid derivative or a pharmacologically acceptable salt thereof, which is useful as a lipopolysaccharide (LPS) inhibitor.
- LPS lipopolysaccharide
- the present invention also relates to a novel intermediate compound useful for synthesizing the hydroxamic acid-based sulfonic acid derivative.
- Sepsis is defined as the systemic inflammatory response syndrome associated with infection [Bone RC: Ann. Intern. Med. 115, 457 (1991)].
- Endotoxin a component of the cell wall, excessively penetrates the blood from the primary foci and is distributed throughout the body via the circulatory system.
- Endotoxin is lipopolysaccharide (LPS) present in the outer membrane of the cell, which is released with the death of Gram-negative bacteria.
- LPS lipopolysaccharide
- It is a macrophage, neutrophil, and lymphocyte in vivo. It stimulates inflammatory cells and vascular endothelial cells to produce inflammatory cytokines (IL-1, IL-16, IL-8, etc.) including TNF (tumour necrosis factor ⁇ ).
- IL-1, IL-16, IL-8, etc. inflammatory cytokines
- TNF tumor necrosis factor ⁇
- the endotoxin removal column developed as a medical material has been confirmed to be effective in clinical practice [Kazuhiko Hanazawa et al., ICU and CCU, 197 (1999)], but is expensive and limited to use within insurance coverage. There is.
- the above facts suggest the importance of endotoxin in the pathogenesis of sepsis and reduce the molecular weight of endotoxin itself, which is located upstream of various inflammatory cytokines including TNF ⁇ r) However, it is promising as a new drug for preventing and treating sepsis.
- Hydroxamic acid derivatives have been studied as MMP (matrix metalloproteinase) inhibitors so far, and many of these inhibitors have an inhibitory effect on inflammatory sites, especially TNF. It has been reported. Although many of these are being studied as preventive and therapeutic agents for sepsis (for example, WO94 / 19090, etc.), they have not yet reached clinical application. On the other hand, no endotoxin (LPS) inhibitory action of hydroxamic acid derivatives has been reported so far.
- MMP matrix metalloproteinase
- the present invention has been made based on the above background art, and an object thereof is to provide a novel hydroxamic acid-based sulfonic acid derivative or a pharmaceutically acceptable salt thereof useful as an LPS inhibitor. It is in. .
- the present inventors have found that a hydroxamic acid-based sulfonic acid derivative or a pharmacologically acceptable salt thereof has an LPS inhibitory effect, and further, in animal models, that the compound of the present invention inhibits an increase in LPS. Thus, the present invention was completed.
- the present invention is as follows.
- X represents hydrogen or a protecting group for a hydroxyl group
- R 1 is hydrogen, alkyl, arylalkyl, heteroarylalkyl, heteroarylalkylthioalkyl, heteroarylthioalkyl, arylthioalkyl, alkylthioalkyl, arylalkylthioalkyl, fluorimidoalkyl, alkenyl, or — (CH 2 )!-A [1 is an integer of any one of 1 to 4, and A is (a) bonded by a nitrogen atom, and (b) as a further hetero atom at a position not adjacent to the bonding atom.
- 2 is hydrogen, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl Alkyl, cycloalkylalkyl or aryl,
- Y represents 0, NR 7 (R 7 is synonymous with R 2 ), or S,
- n an integer from 1 to 6
- R 3 represents hydrogen, halogen (fluorine, chlorine, bromine, iodine), hydroxyl group, trifluoromethyl, cyano, nitro, amino, alkyl, alkoxy, acylyl, carnomoyl, lower alkylamino, or di-lower alkylamino group;
- R 8 is hydrogen, lower alkyl, Ariru, Heteroariru, ⁇ Li one Ruarukiru represents a hetero ⁇ reel alkyl.
- NR 1 0 R 1 1 [R 1 0 and R 1 1 are the same or or different, are each hydrogen, lower alkyl.
- Le, ⁇ reel alkyl, Heteroariru represents a hetero ⁇ reel alkyl or ⁇ Li one le, or R 1 0 and R 1 1 is a together with the adjacent nitrogen atom connexion It may form a heterocyclic ring which may be substituted.
- arylalkyl, heteroarylalkyl, heteroarylalkylthioalkyl, heteroarylthioalkyl, arylthioalkyl, arylalkylthioalkyl, fluorimidoalkyl, aryl, and heteroaryl have a substituent.
- You may. A hydroxamic acid-based sulfonic acid derivative represented by or a pharmacologically acceptable salt thereof,
- X represents hydrogen or a protecting group for a hydroxyl group
- R 1 is hydrogen, alkyl, arylalkyl, heteroarylalkyl, heteroaryl Reel alkylthioalkyl, heteroarylthioalkyl, arylthioalkyl, alkylthioalkyl, arylalkylthioalkyl, fluorimidoalkyl, alkenyl, or 1 (CH 2 )! -A (1 is any of 1-4 Wherein A is (a) linked by a nitrogen atom; and (b) at least one atom selected from nitrogen, oxygen and sulfur as a further heteroatom at a position not adjacent to the bonded nitrogen atom.
- R 2 represents hydrogen, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl or aryl,
- R 12 is a characteristic group of a natural or non-natural amino acid where the functional group present may be protected
- R 6 represents hydrogen, lower alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl
- ⁇ represents an alkylene having 1 to 6 carbon atoms, phenylene or naphthylene,
- arylalkyl may have a substituent.
- R 9 represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl
- R 13 is
- A is 1 to 4 Is an integer of any one of the following: A is (a) a bond bonded by a nitrogen atom, and (b) at least one kind selected from nitrogen, oxygen and sulfur as a further heteroatom at a position not adjacent to the bonded nitrogen atom.
- R 2 represents hydrogen, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl or aryl;
- Y represents 0, NR 7 (R 7 is the same as 2 ), or S,
- n an integer from 1 to 6
- R 3 represents hydrogen, halogen (fluorine, chlorine, bromine, iodine) ⁇ hydroxyl group trifluoromethyl, cyano, nitro, amino, alkyl, alkoxy, acyloxy, carbamoyl, lower alkylamino, di-lower alkylamino,
- 9 represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl
- R 13 is
- a [1 is an integer of any one of 1 to 4, and A is (a) bonded by a nitrogen atom, and (b) as a further heteroatom at a position not adjacent to the bonded nitrogen atom, It may contain at least one atom selected from sulfur, (c) for one or both carbon atoms adjacent to said bonding atom, is substituted by oxo, and (d) benzo-condensed or Represents a 5- or 6-membered 3-nitrogen heterocycle which may be substituted by lower alkyl or oxo on the other carbon atoms described above and / or substituted by lower alkyl or phenyl on another nitrogen atom; .
- COOR 14 R 14 is hydrogen, alkyl, aryla
- R 2 represents hydrogen, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl or aryl,
- R 12 is a characteristic group of a natural or non-natural single amino acid, wherein the functional group present may be protected,
- R 6 represents hydrogen, lower alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl
- Z represents alkylene, phenylene or naphthylene having 1 to 6 carbon atoms.
- an LPS inhibitor comprising, as an active ingredient, a hydroxamic acid-based sulfonic acid derivative or a pharmaceutically acceptable salt thereof according to any of (1) to (9) above,
- R 1 s R 2 , R 3 , R 7 , R 9 The “alkyl” in R 13 and R 14 is a linear or branched alkyl having 1 to 10 carbon atoms, for example, methyl, ethyl And n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-octyl and n-decyl.
- the “lower alkyl” in R 3 , R 6 , R 8 , R 10 and R 11 is a straight-chain or branched alkyl having 1 to 6 carbon atoms, and in one row, methyl, ethyl, n-propyl , Isopropyl, n-butyl, isoptyl, sec-butyl, tert-butyl And n-pentyl, isopentyl, n-hexyl and the like.
- An ⁇ aryl '' in R 2 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 14 is an aryl having 6 to 10 carbon atoms, such as phenyl, naphthyl, or Examples include ortho-fused bicyclic groups having 8 to 10 ring atoms and at least one ring being an aromatic ring (eg, indenyl and the like), and preferably phenyl.
- Heteroaryl in R 6 , R 8 , R 10 and R 11 is a 5- to 6-membered ring having carbon atoms and 1 to 4 heteroatoms (oxygen, sulfur or) or 8 to 10 derived therefrom.
- Ortho-fused bicyclic heteroaryl with two ring atoms especially benzo 'derivatives fused to a benzene ring, or those derived by fusing a propidylene, trimethylene or tetramethylene group to it, and its stable N-year-old oxide and the like, for example, pyrrolyl, pyrrolinyl, furyl, chenyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-
- “Cycloalkyl” in R 2 is cycloalkyl having 3 to 7 carbon atoms, and examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
- cycloalkyl part of “cycloanoalkylalkyl” for R 2 is the same as the above “cycloalkyl”, and the alkyl part is the same as the above “lower alkyl”.
- This Examples of the cycloalkylalkyl as above include cyclopropylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, 3-cyclopentylpropyl, cyclohexylmethyl, 2-cyclohexylethyl, cycloheptylmethyl and the like.
- Alkeniru in R 1 and R 1 3 is Ri alkenyl der of 2-6 carbon atoms, e.g., vinyl, Ariru, 3-heptenyl, hexenyl, and the like to 5.
- R 1, R 2, R 6 , R 7, R 8, R 9, 1 0, R 1 1: 1 3 your good beauty Ariru part is same as the above-mentioned "Ariru” of " ⁇ reel alkyl” in R 1 4 And the alkyl portion is the same as the above “lower alkyl”.
- Such arylalkyls include, for example, benzyl, phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl, 2- (1-naphthyl) ethyl, 2- (2-naphthyl) ethyl, 3 -(1-naphthyl) propyl, 3- (2-naphthyl) propyl and the like.
- heteroaryl portion of “heteroarylalkyl” in It Dck and R 1 ' 4 is up. # 3 Same as “heteroaryl”, and the alkyl part is the same as “lower alkyl” described above.
- heteroarylalkyl examples include 2-pyrrolylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-cheninolemethyl, 2- (2-pyridyl) ethyl, 2- (3 —Pyridinole) ethyl, 2- (4-pyridyl) ethyl, 3- (2-pyrrolyl) propyl and the like.
- alkyl part in the alkylthio part of “azirealkylthioalkyl” in R 1 and R 13 is the same as the above “alkyl”, and the remaining alkyl parts are the same as the above “lower alkyl”.
- alkylthioalkyl include methylthiomethyl, ethylthiomethyl, ⁇ -propylthiomethyl, isopropylthiomethyl, ⁇ -butylthiomethyl, isobutylthiomethyl, sec-butylthiomethyl, tert-butylthiomethyl and the like.
- aryl part of “arylthioalkyl” in R 1 and R 13 is the same as the above “aryl”, and the alkyl part is the same as the above “lower alkyl”.
- arylenethioanolekyi include, for example, phenylthiomethyl, Tilthiomethyl, 2-naphthylthiomethyl and the like.
- Teroariru unit in R 1 and R 1 3 to the "Heteroari one Lucio alkyl" is the same as the "Heteroariru” alkyl portion is the same as the above “lower alkyl”.
- Such heteroarylthioalkynoles include, for example, 2-pyrrolylthiomethyl, 2-pyridylthiomethyl, 3-pyridylthiomethyl, 4-pyridylthiomethyl, 2- chelylthiomethyl and the like.
- aryl alkyl portion of “arylalkylthioalkyl” in R 1 and R 13 is the same as the above “arylalkyl”, and the remaining alkyl portions are the same as the above “lower alkyl”.
- arylalkylthioalkyl include benzylthiomethyl, phenethylthiomethyl and the like.
- heteroarylalkyl part of “heteroarylalkylthioalkyl” in R 1 and R 13 is the same as the above “heteroarylalkyl”, and the remaining alkyl parts are the same as the above “lower alkyl”.
- heteroarylalkylthioalkyl include 2-pyrrolylmethylthiomethyl, 2-pyridylmethylthiomethyl, 3-pyridylmethylthiomethyl, 4-pyridylmethylthiomethyl, 2-phenylmethylthiomethyl and the like. Is mentioned.
- the alkyl part of “phthalimidoalkyl” in R 1 and R 13 is the same as the above “lower alkyl”.
- Examples of such a phthalimidoalkyl include fluorimidomethyl, 2-furimidoethyl and the like.
- a in R 1 and one of (CH 2 ) 1 —A in R 13 is a nitrogen-containing heterocycle linked by a nitrogen atom, and examples thereof include the following groups.
- R '' represents hydrogen, lower anoalkyl or phenyl
- Q represents —CO— ⁇ —CH 2 —, —CH (lower alkyl) —, — C (lower alkyl) 2 —, one NH—, one N (lower alkyl) one or one 0—, and T , Represents -hi, - ⁇ - or - ⁇ (lower alkyl) one.
- nitrogen-containing hetero ring examples include, for example, 2-oxo-1-pyrrolidinyl, 2,5-dioxo-1-pyrrolidinyl, 1,2-dimethyl-3,5-dioxo-1,2,4-triazolidine-14- 1, 3-methyl-1,2,5-dioxo-1-1-imidazolidinyl, 3,4,4-trimethyl-1,2,5-dioxo-1-imidazolidinyl, 2-methyl-1,5-dioxo-1,2,4- Oxadiazolidine-1 4 ⁇ Yl, 3-methyl-2,4,5-trioxo_1-imidazolidinyl, 2,5-dioxo-3-phenyl-11-imidazolidinyl and 2,6-dioxopiperidino, etc.
- arylalkyl, heteroarylalkyl, heteroarylthioalkyl, arylarylthioalkyl, arylalkylthioalkyl, heteroarylalkylthioalkyl, phthalimidoalkyl, aryl and heteroaryl are, for example, halogen (fluorine, chlorine , Bromine, iodine), hydroxyl nitro, cyano, trifluoromethyl, lower alkyl (but arylalkyl, heteroarylalkyl, heteroarylthioalkyl, arylthioalkyl, arylalkylthioalkyl, furylimide is not to replace the alkyl portion of the alkyl), alkoxy, alkylthio, formyl, Ashiruokishi, Okiso, phenylene Le, ⁇ reel alkyl, carboxyl, one CO OR a [R a is lower alkyl, ⁇ Shows the Ruarukiru or Arir
- Alkoxy refers to alkoxy having 1 to 6 carbon atoms which may be linear or branched, and examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy and the like.
- alkylthio is the same as the above “lower alkyl”.
- alkylthio examples include methylthio, ethylthio, n-propylthio, and isopropylthio.
- “Asiloxy” is alkanoyloxy having 2 to 6 carbon atoms which may be linear or branched, and includes, for example, acetyloxy, propionyloxy, ptyryloxy, valeryloxy, bivaloyloxy, hexanoyloxy and the like.
- the arylalkyl part of “arylalkyloxyalkyl” is the same as the above “arylalkyl”, and the remaining alkyl parts are the same as the above “lower alkyl”. Examples of such arylalkyloxyalkyl include benzyloxymethyl, phenethyloxymethyl and the like.
- An “optionally substituted heterocycle” formed by R 1 Q and R 11 together with an adjacent nitrogen atom has a carbon atom and at least one nitrogen atom, and further heterocycle in the ring. It may contain at least one kind of atom selected from nitrogen, oxygen and sulfur, and is a 4- to 7-membered group which may be substituted by oxo with respect to a carbon atom constituting the ring. Further, an aromatic group such as benzene may be condensed using two adjacent carbon atoms constituting the hetero group.
- Such heterocycles include, for example, azetidino, 1-pyrrolidinyl, piperidino, 1
- heteroalkyl contains a nitrogen atom as a further hetero atom such as 1-piperazinyl
- a lower alkyl as described above
- an arylalkyl as described above
- heteroalkyl ⁇ reel alkyl (wherein the same way), Ariru (as above), Heteroariru (as above), single COOR a (R a is a group or Ashiru represented by the same) has been replaced You may.
- a group represented by one COR a and Ashiru, the R a are as defined above.
- the characteristic group Fei single amino acid other than natural or nature of the R 1 2, H 2 N- CH (R) -COOH in natural or nature other than shown - Ru group R der in the amino acid.
- characteristic groups derived from naturally occurring amino acids are as follows, and the corresponding amino acids are shown in parentheses: hydrogen (glycine), methyl (alanine), isopropyl (valine), isobutyl (leucine), Penzil (furanalanine), p-hydroxybenzyl (tyrosine), hydroxymethyl (serine), mercaptomethyl (cysteine), 1-hydroxyethyl (threonine), 2-methylthioethyl (methionine), carboxymethyl (aspartate) , 2-carboxyethyl (glutamic acid), 2-indolylmethyl (tributophan), 4-imidazolylmethyl (histidine), 4-aminobutynole (lysine), 3-guanidino Propyl (arginine).
- Examples of characteristic groups derived from one non-natural amino acid are as follows, and the corresponding non-natural amino acid is shown in parentheses: ethyl (H-amino-n-butyric acid), n-propyl (H-amino-n —Pentanoic acid), n-butyl ( ⁇ -amino-n-heptanoic acid), n-heptyl (hy-amino-n-nonanoic acid), cyclohexylmethyl (cyclohexylalanine), phenyl ( ⁇ -aminophenol) Acetic acid), 2-phenylethyl (homophenylalanine), 1-naphthyl (1-amino-1-naphthylacetic acid), 2-naphthyl (1-amino-1-naphthylacetic acid), phenethyl (1-amino-3-) Phenylbutanoic acid), 1-methylbenzyl (? -
- Any (reactive) functional groups present in R 1 2 may be protected by methods known in peptide chemistry.
- an amino group can be protected in the form of a tert-butoxycarbonyl, benzyloxycarbonyl or isobornyloxycarbonyl or fluorimido group.
- Carboxyl groups can be protected in the form of methyl, ethyl, tert-butyl, benzyl and the like.
- Hydroxy groups can be protected in the form of tert-butyl, benzyl, or tetrahydrovinyl alcohol, or in the form of acetate.
- Mercapto groups can be protected by tert-butyl, benzyl, or similar groups.
- Examples of the “protecting group for hydroxyl group” in X include, for example, arylalkyl, aryl, heteroaryl, silyl (eg, trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, etc.), 2-tetrahydrovinylyl And the like.
- the arylalkyl, aryl and heteroaryl are, for example, halogen (fluorine, chlorine, bromine, iodine), hydroxyl nitro, cyano, trifluoromethyl, lower alkyl (substituted with the alkyl moiety of arylalkyl) ), Alkoxy, alkylthio, formyl, acyloxy, oxo, phenyl, arylalkyl, carboxyl, —COOR a [ Ra represents lower alkyl, arylalkyl or aryl.
- Lubamoyl amino, lower alkylamino, di-lower alkylamino, guanidinium And may have one or more substituents selected from hydroxy, sulfonyloxy, arylalkyloxyalkyl and the like.
- hydroxyl-protecting group in the compound of the present invention silyl, 2-tetrahydroviranyl, pendyl and the like are preferable.
- alkylene in Z represents a methylene chain having 1 to 5 carbon atoms, and examples thereof include methylene, ethylene, propylene, butylene, and pentylene.
- the “phenylene” in Z represents a divalent aromatic hydrocarbon group represented by one C 6 H 4 —, for example, 1, 2-, 1, 3-, or 1,4-phenylene Are mentioned.
- the “naphthylene” in Z represents a divalent aromatic represented by 0 H 6 —; represents a hydrogen group, such as 1, 2—, 1, 4—, 1, 5—, 2, 5 — Or 2,8_naphthalene.
- Phenylene and naphthylene in Z are, for example, halogen (fluorine, chlorine, bromine, iodine), hydroxyl, nitro, cyano, trifluoromethyl, lower alkyl, alkoxy, acyloxy, hydroxysulfonyl, hydroxysulfonyloxy May be substituted with one or more substituents selected from
- “lower alkyl”, “alkoxy” and “acyloxy” are the same as in Part 3.
- Hydroxamic acid sulfonic acid derivatives represented by the formulas (I) and (II) and compounds represented by the formulas (III) and (IV) or pharmacologically acceptable salts thereof have an asymmetric carbon. Therefore, it can exist as an optically active form or a racemic form, and the racemic form can be separated into each optically active form by a method known per se.
- the hydroxamic acid-based sulfonic acid derivative or a pharmacologically acceptable salt thereof has an additional asymmetric carbon, the compound exists as a diastereomer mixture or as a single diastereomer. These can also be separated from each other by a method known per se.
- hydroxamic acid-based sulfonic acid derivative or a pharmaceutically acceptable salt thereof can exhibit polymorphism, and can exist as more than one tautomer. Can exist as solvates. Therefore, the present invention relates to any of the above-mentioned # ⁇ It includes tautomers, solvates, and any mixtures thereof. Optically active, racemic and diastereomers are also included in the scope of the present invention.
- Examples of pharmacologically acceptable salts of the hydroxamic acid-based sulfonic acid derivatives represented by the formulas (I) and (II) or the compounds represented by the formulas (III) and (IV) include, for example, alkali metal salts (lithium , Sodium, potassium, etc.), alkaline earth metal salts (salts with calcium, magnesium, etc.), aluminum salts, ammonium salts, organic bases (triethylamine, morpholine, pyridine, trietylamine, trishydroxy) Salts with natural amino acids (such as alanine, phenylalanine, histidine, lysine, and arginine).
- pharmacologically acceptable salts include, for example, inorganic acid addition salts (salts with hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc.), organic acid addition salts (meta acid) Sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, oxalic acid, citric acid, malonic acid, fumaric acid, glutaric acid, adipic acid, maleic acid, tartaric acid, succinic acid, mandelic acid , Malic acid, etc.), and amino acid (glutamic acid, aspartic acid, etc.). Further, for crystallization, oxalic acid may be used to form a salt.
- Preferred embodiments of the hydroxamic acid-based sulfonic acid derivatives represented by the formulas (I) and (II) and the compounds represented by the formulas (II I) and (IV) are a free acid or a pharmacologically acceptable compound. Crystallization is possible in both forms, and any derivative and its isomer can be produced in high purity and in large quantities.
- R 1 is phthalimidomethyl Or a pharmacologically acceptable salt thereof.
- a hydroxamic acid-based sulfonic acid derivative wherein R 2 is isobutyl, or a pharmacologically acceptable salt thereof in formulas (I) and (II), a hydroxamic acid-based sulfonic acid derivative wherein R 2 is isobutyl, or a pharmacologically acceptable salt thereof.
- a hydroxamic acid derivative wherein R 3 is hydrogen or a pharmaceutically acceptable salt thereof;
- R 4 is NHCH 3 or NHC 6 H 5
- a hydroxamic acid derivative or a pharmacologically acceptable salt thereof in the formula (II), a hydroxamic acid-based sulfonic acid derivative wherein R 12 is benzyl or a pharmacologically acceptable salt thereof in the formula (II)
- hydroxamic acid-based sulfonic acid derivatives wherein R 6 is hydrogen, or pharmacologically acceptable salts thereof.
- the difficult examples 1, 2, 10, 10, 11, 13, 14, 15, 15, 17, 19, 21, 21 and 22 Chemical formulas are preferred compounds.
- n represents an integer of 1 to 6
- R 9 ′ has the same meaning as R 9 (excluding hydrogen)
- RR 3 , R 4 , X and Y have the same meanings as above.
- (I) or a pharmacologically acceptable salt thereof can be obtained by using a carboxylic acid (VI I) as a raw material and an amino derivative (VI II) to activate the C-terminal in peptide synthesis [for example, the basics of peptide synthesis and Experiments (see Maruzen Shoten, Izumiya et al., ⁇ 91)], the intermediate compound (Via), sulfonic acid derivative (Va) and sulfonic acid derivative
- the amino derivative (VIII) can be produced, for example, by the method described below.
- Step 1 is a step of preparing an intermediate compound (Via) by reacting a carboxylic acid (VII) with an amino derivative (VIII).
- the intermediate compound (VIa) is prepared by reacting carboxylic acid (VII) with isobutyl carbonate in the presence of an amine base such as triethylamine or N-methylmorpholine and then reacting the amino derivative (VIII). Can be obtained.
- an aprotic solvent such as tetrahydrofuran (THF), methylene chloride, ethyl acetate, N, N-dimethylformamide (DMF) is used, and the reaction can be carried out at a temperature of 15 ° C to room temperature.
- the acid chloride is once prepared by reacting the carboxylic acid (VI I) with oxalyl chloride or thionyl chloride.
- the solvent methylene chloride or a hydrocarbon solvent such as benzene or toluene is used, and the reaction is performed at ⁇ 15 ° C. to room temperature or under heating.
- the intermediate compound (Via) can be obtained by reacting the obtained acid chloride with an amino derivative (VIII) in the presence of an amine base such as triethylamine or pyridine.
- an aprotic solvent such as THF, ethyl acetate, DMF, methylene chloride, benzene, and toluene is used, and the reaction can be performed at a temperature of 15 ° C. to room temperature or under heating.
- the intermediate compound (Via) can be added to a carboxylic acid (VI I) and an amino derivative (VI II) as a condensing agent in the presence of an amine base such as triethylamine or N-methylmorpholine as a condensing agent with 1,3-dicyclohexylcarbodiimide ( DCC) and 1 -Hydroxybenzotriazomonozole (HOBt) or 3-hydroxy-1,3,4-dihydro-14-oxo-1,2,3-benzotriazine (HOOBt) at room temperature or below. it can.
- an amine base such as triethylamine or N-methylmorpholine
- DCC 1,3-dicyclohexylcarbodiimide
- HOBt 1 -Hydroxybenzotriazomonozole
- HOOBt 3-hydroxy-1,3,4-dihydro-14-oxo-1,2,3-benzotriazine
- DCC 1,3-diisopropylcarbodiimide
- DIPC I 1,3-diisopropylcarbodiimide
- WSCI-HC1 1-ethyl-3- (3-dimethylaminopropyl) carbodiimidide hydrochloride
- BOP reagent hexafluorolol
- Benzotriazolic acid 1-yloxytris (dimethylamino) phosphonium (BOP reagent) and the like can also be used.
- an aprotic solvent such as THF, methylene chloride, ethyl acetate, DMF, and pyridine is used.
- the active ester is prepared once by reacting carboxylic acid (VI I) with a phenol derivative such as pentafluorophenol or N-hydroxysuccinimide with a condensing agent such as DCC.
- the amine base is used as needed, and examples of the amine base used include triethylamine and N-methylmorpholine.
- an aprotic solvent such as THF or DMF methylene chloride is used, and the reaction is performed at room temperature or lower.
- the intermediate compound (Via) can be obtained by reacting the obtained active ester with an amino derivative (VIII).
- the amine base is used as needed, and examples of the amine base used include triethylamine and N-methylmorpholine.
- an aprotic solvent such as THF, DMF, and methylene chloride is used, and the reaction can be carried out at room temperature or lower.
- the sulfonic acid derivative (Va) can be obtained by reacting the intermediate compound (Via) with a haloalkanesulfonic acid or sultone in the presence of a salt such as potassium carbonate or cesium carbonate.
- a salt such as potassium carbonate or cesium carbonate.
- an aprotic solvent such as DMF, acetonitrile, and acetone is used, and the reaction can be carried out at ⁇ 15 ° C. to room temperature or under heating.
- Step 3 converts sulfonic acid derivative (Va) to sulfonic acid derivative (I lia)
- Step 3 converts sulfonic acid derivative (Va) to sulfonic acid derivative (I lia)
- R 9 ′ is a compound that can be removed with an acid such as a tert-butyl group
- the sulfonic acid derivative (Va) is converted to a sulfonic acid derivative (Ilia) by reacting with hydrogen chloride or trifluorosulfonic acid.
- the solvent an ether-based solvent such as 1,4-dioxane or methylene chloride is used, and the reaction can be performed at room temperature or lower.
- step 4 sulfonic acid derivative (Ilia) is converted to silyl (trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, etc.), tert-butyl, benzyl, benzyloxymethyl, p-methoxybenzyl, 2-nitro Benzyl or 2-tetrahydroviranyl (Chem. Pharm. Bull. Jpn. 23, 167, 1975) protected or unprotected hydroxylamine (XONH 2 ; X is as defined above) to react with hydroxam
- This is a step of converting to an acid-based sulfonic acid derivative (I).
- the conditions in Step 1 can be applied.
- Rokishiruamin is deprotection conditions typically hydroxyl groups after the reaction [TW Greene et. Al., PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, 2 nd ed., (JOHN WILEY & S0NS, Inc.)] by the Protecting groups can be removed.
- n represents an integer of 1 to 6, and R 1 , R 2 , R 3 , R 4 , R 9 ′ and Y are as defined above. ]
- Step 5 is a step of producing the sulfonic acid derivative (Va) by reacting the carboxylic acid (VII) with the amino derivative (IX). This step can be performed in the same manner as in step 1.
- hydroxamic acid-based sulfonic acid derivative (I) of the present invention can also be produced by the method shown in Scheme 3 below.
- n represents an integer of 1 to 6
- X 5 and W have the same meaning as X, and may be the same or different
- R 1 , R 2 , R 3 , R 4 , X and Y are Synonymous with Part 3.
- Step 6 is a step of producing the sulfonic acid derivative (la) by reacting the carboxylic acid (X) with the amino derivative (IX). This step can be performed in the same manner as in step 1.
- Step 7 is a step of converting the sulfonic acid derivative (la) into a hydroxamic acid-based sulfonic acid derivative (I) .
- W is the same as or different from X, it can be performed in the same manner as in Step 4. it can.
- the carboxylic acid (X) can be produced, for example, by the method described in Scheme 6 below.
- Amino derivatives (VIII) and (IX) can be produced, for example, by the method described in Scheme 5 below.
- the introduction of the desired substituent R 1 can be carried out by using the carboxylic acid (VI I) or (X) having the substituent without any special steps, by the method shown in the Shuku 3 scheme 1 to 3.
- the method shown in Scheme 4 below It can also be done by law (
- n represents an integer from 1 to 6
- R 1 represents heteroarylthioalkyl, arylarylthioalkyl, heteroarylalkylthioalkyl or arylalkylthioalkyl
- R 14 ′ represents R 14 has the same meaning (excluding hydrogen)
- R 2 , R 3 , R 4 , R 9 ′ and Y have the same meanings as described above.
- Step 8 is a step of obtaining an intermediate compound (VIb) by reacting the carboxylic acid (XI) with the amino derivative (VIII). This step can be performed in the same manner as in step 1.
- the carboxylic acid (XI) as a raw material is a compound described in a literature (JP-A-7-157470, etc.) or is prepared by a conventional method based on these literatures.
- Step 9 produces a sulfonic acid derivative (Vb) by reacting the intermediate compound (VIb) with a haloalkanesulfonic acid or sultone: ⁇ .
- This step can be performed in the same manner as in step 2.
- Step 10 is a step of obtaining a sulfonic acid derivative (Vb) by reacting the carboxylic acid (XI) with the amino derivative (IX). This step can be performed in the same manner as in 1.
- step 11 the substituents in the sulfonic acid derivative (Vb)! This is the step of removing the '′ and R 14 ′ to obtain the sulfonic acid derivative (II lb).
- R 9 ′ and 4 are benzyl groups
- the reaction can be carried out at normal pressure or under pressure by a usual catalytic hydrogenation reaction in the presence of a metal catalyst.
- the metal catalyst palladium carbon or palladium black can be used
- the solvent is an ether solvent such as 1,4-dioxane, an ester solvent such as ethyl acetate, or a solvent such as methanol, ethanol, or isopropyl alcohol.
- the reaction can be performed from room temperature to under heating using an alcohol solvent.
- Step 12 is to convert the sulfonic acid derivative (II lb) obtained in step 11 to a sulfonic acid derivative (IIIc) by decarboxylation. It can be carried out in the presence of a tertiary amine such as N "-methylmorpholine or triethylamine, or at room temperature or under heating, depending on the use of hydrocarbon solvents such as n-hexane, benzene, and toluene. .
- a tertiary amine such as N "-methylmorpholine or triethylamine
- Step 13 is a step in which the sulfonic acid derivative (IIb) obtained in step 11 is reacted with formaldehyde in the presence of a secondary amine to convert it into a sulfonic acid derivative (IIId).
- a secondary amine As the secondary amine, piperidine, getylamine, morpholine or the like is used, and the secondary amine can be heated from room temperature to an amide-based solvent such as methanol or ethanol, or an amide-based solvent such as DMF from room temperature.
- step 14 the sulfonic acid derivative (IIId) obtained in step 13 is used as a nucleophile for arylaryl, heteroarylthiol, alkylthiol, heteroarylalkylthiol or arylalkylthiol.
- This reaction can be carried out without a solvent or in a solvent such as methylene chloride, a chlorinated hydrocarbon-based solvent, an alcohol-based solvent such as methanol, or an amide-based solvent such as DMF from room temperature to under carothermal heat.
- a solvent such as methylene chloride, a chlorinated hydrocarbon-based solvent, an alcohol-based solvent such as methanol, or an amide-based solvent such as DMF from room temperature to under carothermal heat.
- n represents an integer of 1 to 6
- A represents an amino-protecting group such as tert-butoxycarbonyl, benzyloxycarbonyl, etc.
- L represents alkoxy, hydroxyl 3 and a derivative thereof.
- a halogen atom such as chlorine, bromine or iodine or a sulfonic acid ester such as methanesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy, etc.
- R 3 , R 4 and Y have the same meaning as in Part 3 is there.
- Step 15 is a step of producing a compound (XIlb) by reacting the compound (XIIa) with various amines or alcohols. This:! 3 ⁇ 4 can be performed in the same manner as in 1.
- Step 16 is a step of producing an amino derivative (VIII) by deprotecting the protecting group of the amino group of the compound (XIlb).
- the protecting group A ' is a tert-butoxycarbonyl group
- it can be removed under acidic conditions such as trifluoroacetic acid, hydrogen chloride-containing dioxane, hydrogen chloride-containing methanol, and hydrogen bromide-containing acetic acid.
- inert solvents used include halogenated hydrocarbon solvents such as methylene chloride and chloroform, ether solvents such as geethylether, THF, and dioxane, methanol, ethanol, n-propyl alcohol, and isopropyl alcohol.
- Preferred are alcoholic solvents such as acetic acid, and organic acids such as acetic acid.
- the reaction temperature is usually 0 to 100 ° C, preferably 0 to 50 ° C.
- the reaction time is generally 15 minutes to 12 hours, preferably 15 minutes to 4 hours.
- a method in which the protecting group A ′ is removed by treating with an acid in which the protecting group A ′ is a pendoxycarbonyl group or a method in which the protecting group A ′ is removed by catalytic reduction is preferable.
- trifluoromethanesulfonic acid is preferred.
- the solvent used is preferably methylene chloride.
- the reaction and the reaction time are preferably at 0 to 50 ° C for 5 minutes to 6 hours.
- Palladium carbon or palladium black is suitable as the catalyst used in the method by catalytic reduction.
- the solvent used include alcoholic solvents such as methanol, ethanol, n-propyl alcohol, and isopropyl alcohol; ether solvents such as dimethyl ether, tetrahydrofuran, 1,4-dioxane; and ethyl acetate. Ester solvents are preferred.
- the pressure of hydrogen is usually 1 to 10 atm, and the reaction temperature and the reaction time are preferably 0 to: L 00 ° C for 5 minutes to 24 hours. Artificial culm 17
- Step 17 is a step of producing a compound (XIIc) by reacting the compound (XI lb) with a haloalkanesulfonic acid or sultone. This step can be performed in the same manner as in step 2.
- Step 18 is a step of producing an amino derivative (IX) by deprotecting the protecting group of the amino group of the compound (XIIc), and can be carried out in the same manner as in step 16. .
- This is a method in which an alkylating agent is allowed to act on the compound (XI lb) to convert it into compound (XI Id: L lipid), which can be carried out in the same manner as in Step 2.
- the alkylating agent include dihalogenated alkyl having a desired carbon chain, such as dibromomethane, 1,2-dibromoethane, 1-chloro-3-bromopropane, 1-chloro-14-bromobutane and 1-chlorobutane. It can be carried out using 5-bromopentene.
- Step 19-2 Stepwise synthesis
- This method comprises the following three steps i) to Li i).
- aprotic solvents such as acetonitrile, THF, dioxane, methylene chloride, and chloroform can be used.
- the reaction temperature in this step is preferably from 15 ° C.
- a desired sulfonitrile in the presence of an amine base.
- the sulfonylating agent methanesulfonic anhydride, trifluoromethanesulfonic anhydride or P-toluenesulfonyl chloride is preferable, and as the amine salt group, triethylamine, pyridine, 2,6-lutidine, 2,4,4 6-collidine or diisopropylethylamine is preferred.
- an aprotic solvent such as acetonitrile, THF, dioxane, toluene, methyl chloride orifice and the like can be used.
- the reaction temperature in this step is preferably from 15 ° C to room temperature.
- This step can be performed according to the method described in the literature [F. Cortes, Organic Synthesis, II, 564 (1943)].
- Sodium sulfite, sodium sulfite, or the like is suitable as the hydroxysulfonylide.
- water 1 / ⁇ can be a hydroalcoholic.
- the reaction temperature in this step is preferably from room temperature to heating. '
- R 9 ′ and R 14 ′ are the same or taken together as a methylene group (one CH 2 —) or dimethyl methylene [—C (CH 3 ) 2 one]
- R 15 ′ has the same meaning as R 9 ′ and R 14 ′ (provided that R 15 ′ is selected from a group different from R 9 ′ and R 14 ′); RR 2 , R 9 ′, R 14 ′ and X are as defined above.
- Step 21 is a step of converting compound (XIa) into compound (Xlb) by deprotection.
- R 15 ′ is a benzyl group and R 9 ′ and R 14 ′ are a t-butyl group
- the reaction can be performed in the same manner as in Step 3, and the opposite i is represented by (R 15 ′: t-butyl group, R 9 ′ and R 14 ′: pendyl) can be carried out in the same manner as in Step 11.
- the compound (XIa) as a raw material is a compound described in JP-A-7-157470, or is prepared by a conventional method based on these documents.
- Step 22 is to form the compound (Xlb) by decarboxylation ⁇ ; This is a conversion step, and can be performed in the same manner as in step 12.
- Step 23 is a step of reacting the compound (Vi la) with N, 0-disubstituted hydroxylamine [X'0N (W) H] to convert it to the compound (Xa).
- N, 0-disubstituted hydroxylamine [ ⁇ 'ON (W) H] is commercially available or obtained by the method described in the literature (C3 ⁇ 4.? Am. Bull. Jpn. 1975, 23, 167.). It can be prepared by a conventional method using the amine [X, ONH 2 ].
- the starting compound (XIla) in Scheme 5 can be produced by the following method.
- R 6 ′ and R 6 have the same meaning as 6 (where R 6 ′ excludes hydrogen), X ′ has the same meaning as X, and R 1 , R 2 , R 6 , R 12 , X and Z are synonymous with the previous statement.]
- the hydroxamic acid-based sulfonic acid derivative (II) of the present invention or a pharmaceutically acceptable salt thereof can be synthesized by the method shown in Scheme 7.
- a carboxylic acid (VI I) and an amino derivative (XVI II) were converted to a C-terminal activation method in peptide synthesis [for example, see Peptide Synthesis Fundamentals and Experiments (Maruzen Shoten, Izumiya et al. P. 91).
- XVI I succinic acid derivative
- the carboxylic acid (VII) as a raw material is as described above, and the amino derivative (XVIII) can be produced, for example, by the method described in Scheme 11 described below.
- Step 25 is a step of producing an intermediate compound (XVI I) by reacting a carboxylic acid (VI I) with an amino derivative (XVI I I), and can be carried out in the same manner as in @l.
- Step 26 is a step of converting the intermediate compound (XVI I) to a succinic acid derivative (XVI), and can be performed in the same manner as in step 3.
- Step 27 is a step of converting the succinic acid derivative (XVI) to the 0-protected hydroxamic acid derivative (XV), and can be performed in the same manner as in step 4.
- Step 28 is a step in which the 0-protected hydroxamic acid derivative (XV) is deprotected and converted to an intermediate compound (XIV).
- R 6 ′ is a benzyl group
- a method of deprotection by catalytic reduction is preferred.
- Palladium carbon or palladium black is suitable as a catalyst for the method of reducing parasites.
- the solvent alcohol solvents such as methanol, ethanol, ⁇ -propyl alcohol and isopropyl alcohol, ether solvents such as getyl ether, THF and 1,4-dioxane, and ester solvents such as ethyl acetate are preferable.
- the pressure of hydrogen is usually 1 to 10
- the reaction temperature and reaction time are preferably 0 to
- L is preferably from 5 minutes to 24 hours at 00 ° C.
- Step 30 is a step of converting the ⁇ -protected hydroxamic acid-based sulfonic acid derivative (XII I) to a hydroxyxamic acid-based sulfone derivative (II).
- the protecting group of the 0-protected hydroxamic acid sulfonic acid derivative (XIII) can be removed by ordinary hydroxyl group deprotection conditions in the same manner as in 13 ⁇ 44.
- the 0-protected hydroxamic acid sulfonic acid derivative (XIII) can also be produced by the method shown in Scheme 8 below.
- Step 31 is a step of producing an intermediate compound (XXa) by reacting the carboxylic acid (VII) with the amino derivative (XIX).
- This ® can be performed in the same way as for 3 ⁇ 4l.
- Step 32 is a step of converting the intermediate compound (XXa) into a succinic acid derivative (Xla). This step can be performed in the same manner as in step 3.
- Step 33 is a step of converting a succinic acid derivative (XXIa) to a 0-protected hydroxamic acid-based sulfonate derivative (XIII). This step can be performed in the same manner as in step 4.
- the 0-protected hydroxamic acid sulfonic acid derivative (XIII) can also be produced by the method shown in the following scheme 9, that is, the same method as scheme 3 in the hydroxamic acid sulfonic acid derivative (I).
- W has the same meaning as X ′ and may be the same or different, and R 1 , R 2 , R 12 , ′′, X ′ and Z have the same meanings as described above. ]
- Step 34 is a step of producing a sulfonic acid derivative (XI la) by reacting a carboxylic acid (X) with an amino derivative (XIX). This step can be performed in the same manner as in step 1.
- Step 35 is a step of converting the sulfonic acid derivative (XIIIa) to a hydroxamic acid-based sulfonic acid derivative (XIII). This: C3 ⁇ 4 can be performed in the same manner as in Step 7.
- the carboxylic acid (X) can be produced according to the above scheme 6, and the amino derivatives (XVI II) and (XIX) are described, for example, in scheme 11 described below. It can be manufactured by a method.
- the introduction of the desired substituent R 1 can be carried out by using the carboxylic acid (VI I) having the substituent by the method shown in the above schemes 7 and 8 without going through any special steps. it can.
- carboxylic acid (XI) and amino derivative (XIX) hydroxamic acid sulfonic acid derivative
- Step 36 is a step in which an intermediate compound (XXIIa) is obtained by reacting the carboxylic acid (XI) with the amino derivative (XIX).
- This step can be performed in the same manner as in step 1.
- the carboxylic acid (XI) as a raw material is a compound described in a document (Japanese Patent Application Laid-Open No. 7-157470, etc.), or is prepared by a conventional method based on these documents.
- Step 37 removes the intermediate compound (XXI I a) substituent in R 9 'and R 1 4', a 3 ⁇ 4 to obtain succinic acid derivative (XXI lb). This can be done in the same way as in step 11.
- Step 38 is a step of converting the succinic acid derivative (XXI Ib) obtained in Step 37 into a succinic acid derivative (XXI Ic) by decarboxylation. This step can be performed in the same manner as in step 12.
- Step 39 is a step of reacting the succinic acid derivative (XXI lb) obtained in step 37 with formaldehyde in the presence of a secondary amine to convert it into a succinic acid derivative (XXI Id). This step can be performed in the same manner as in step 13. ⁇ Process 40
- Step 40 comprises reacting the succinic acid derivative (XXIId) obtained in step 39 with arylthiol, heteroarylthiol, alkylthiol, heteroarylalkylthiol or arylalkylthiol as a nucleophile.
- arylthiol, heteroarylthiol, alkylthiol, heteroarylalkylthiol or arylalkylthiol as a nucleophile.
- A represents an amino protecting group such as tert-butoxycarbonyl, benzyloxycarbonyl and the like, and R 12 , R 6 ′, R 6 ′′ and Z are as defined above.
- Culm 41 represents an amino protecting group such as tert-butoxycarbonyl, benzyloxycarbonyl and the like, and R 12 , R 6 ′, R 6 ′′ and Z are as defined above.
- Step 41 is a step of producing a compound (XXI I lb) by reacting the compound (XXI I Ia) with an alcohol derivative such as benzyl alcohol. This step can be performed in the same manner as in step 1.
- Step 42 is a step for producing an amino derivative (XVI II) by deprotecting the protecting group of the amino group of the compound (XXI IIb), which is carried out in the same manner as @l 6. Can be.
- Step 43 I ⁇ compound (XXI II a) with an amino alkane sulfonic acid derivative: R 6 "-NH-Z- S0 3 H (R 6 '' and Z are as defined above) more compound by reacting (XXI ie): This step can be performed in the same manner as in step 29.
- Step 44 is a step of producing an amino derivative (XIX) by removing the protecting group of the amino group of the compound (XXIlie), and can be carried out in the same manner as in step 16.
- the starting compound (XIlia) in Scheme 10 can be produced by the following method.
- the amino group of the amino acid represented by is protected by an amino-protecting group such as a tert-butoxycarbonyl group or a benzyloxycarbonyl group. Can be prepared.
- the hydroxamic acid-based sulfonic acid derivative of the present invention synthesized in this manner can be obtained by appropriately using known means for separating fibers, for example, means such as concentration, extraction, chromatography, re-tanada, and recrystallization. It can be collected at any purity.
- hydroxamic acid-based sulfonic acid derivative can be produced by a known method.
- various isomers of the hydroxamic acid-based sulfonate derivative can also be produced by a known method.
- hydroxamic acid-based sulfonic acid derivative of the present invention and a pharmacologically acceptable salt thereof have an excellent LPS inhibitory effect on mammals (for example, humans, dogs, cats, etc.) and low toxicity. It is.
- hydroxamic acid-based sulfonic acid derivative and the pharmacologically acceptable salt thereof of the present invention are useful as LPS inhibitors, for example, Useful for the prevention and treatment of rheumatoid arthritis, Crohn's disease, cachexia, myasthenia gravis, systemic lupus erythematosus, asthma, type I diabetes, psoriasis, other autoimmune diseases, inflammatory diseases, etc. .
- hydroxamic acid-based sulfonic acid derivative of the present invention and its pharmacologically acceptable salt are used as pharmaceuticals, granules, tablets, capsules, injections, ointments, ophthalmic solutions are used using pharmacologically acceptable carriers and the like. It can be orally or parenterally administered as a pharmaceutical composition in the form of nasal drops, creams, aerosols and the like.
- the hydroxamic acid-based sulfonic acid derivative and its pharmacologically acceptable salt are excellent in water solubility, so that a water-soluble pharmaceutical composition such as an injection, an ophthalmic solution, a nasal solution, or an infusion is prepared. It is preferable to do.
- hydroxamic acid-based sulfonic acid derivative An effective amount of the hydroxamic acid-based sulfonic acid derivative and its pharmacologically acceptable salt is incorporated into the above preparation.
- the dose of the hydroxamic acid-based sulfonic acid derivative and a pharmacologically acceptable salt thereof varies depending on the administration route, the patient's condition, body weight, or yearly restraint, and can be appropriately set depending on the purpose of administration.
- 1 H-NMR was measured at 270 MHz or 300 MHz.
- the chemical shifts of 1 H—N MR were expressed in relative DEL (values in parts per million (ppm) using tetramethylsilane as an internal standard. (Hz), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet doublet), brs (broadcast rate) Etc.
- Hz s
- singlet d
- d doublet
- t triplet
- q quartet
- m multiplet
- dd doublet doublet
- brs broadcast rate
- a rice product was obtained in the same manner as described in JP-A-4-352757. Purification was performed by the following method. The crude product (607 g, about 1.32 mol) was dissolved in diisopropyl ether (6 L), cyclohexylamine (151 mL, 1.32 mol) was added under ice cooling, and the mixture was stirred for 1.5 hours. . The precipitate was collected by filtration, washed (diisopropyl ether), air-dried, and the obtained solid was suspended in ethyl acetate (0.4 L).
- Example 3 The title compound (16 Og, 0.54 mol) of Example 3 (16 Og, 0.54 mol) was mixed thoroughly with chloroform (80 OmL) and methanol (400 mL) and dissolved gently, and then cooled under ice-cooling (internal temperature 7 ° C). Then, anisol (295 mL, 2.72 mol) and a 4 N hydrochloric acid-dioxane solution (80 OmL) were added, and the mixture was stirred at the same temperature for 2 hours and at room temperature for 2 hours. Diisopropyl ether (2 L) was added to the reaction solution, and the precipitate was collected by filtration, washed with diisopropyl ether, and dried to give the title compound (125 g, quantitative) as a white solid.
- Example 5 To a solution of the title compound (91.2 g, 16 lmmol) of Example 5 (5) in DMF (50 OmL) was added 1,3-propane sultone (21.7) at room temperature. g, 177 mmo1) and cesium carbonate (57.8 g, 177 mmol) were added, and the mixture was stirred for 45 hours. Diisopropyl ether (2 L) was added to the reaction solution, and the precipitate was collected by filtration, washed with ethyl acetate, and dried to give the compound (159 g, 5 quantitative) as a white solid.
- Example 2 The title compound (30.2 Og, 21.8 mmol) in Example 1, (8) was suspended in a mixed solvent consisting of water (5 OmL) -methanol (5 OmL) -THF (5 OmL), and the mixture was stirred at room temperature. , 2.4 N hydrochloric acid (5 OmL) were added, and the mixture was stirred for 3 hours. The methanol and THF were distilled off from the reaction solution under Ji, and the precipitate was collected by filtration and washed with isopropyl alcohol and diisopropyl ether. The obtained precipitate was suspended in water (600 mL) and neutralized with sodium hydrogen carbonate (1.84 g, 21.8 mmol).
- aqueous solution is applied to a synthetic adsorbent column (Diaion HP-20: water, 5 (0% methanol aqueous solution), fractions eluted with a 50% methanol aqueous solution were collected, and concentrated under reduced pressure until a precipitate appeared. The residue was recrystallized from water-isopropyl alcohol to give the title compound (4.01 g, 27%) as white crystals.
- Example 2 (1) To a solution of the title compound of Example 2 (1) (5.82 g, about 7.2 Ommo 1) in methanol (100 mL) was added 5% hydrogen chloride methanol (5 OmL). The mixture was stirred at 30 ° C for 1.5 hours. Diisopropyl ether (45 OmL) was added to the reaction solution, and the precipitate was collected by filtration and washed with diisopropyl ether. The obtained precipitate was recrystallized from water-isopropyl alcohol to give the title compound (2.85 g, 58%) as white crystals.
- Example 3 (1) The title compound of Example 3 (1) was used and synthesized in the same manner as in Example 1 (4).
- Example 1 (2) The title compound of Example 1 (2) was obtained by purification by column chromatography.
- Example 4 Dissolve the title compound of Example 4, (1) (1.54 g, 3.95 mmol) and the title compound of Example 4, (3) (1.70 g, 3.95 mmol) in DMF (30 mL). HOBt-H 2 O (0.61 g, 3.95 mmol), N-methylmorpholine (1.73 mL, 15.7 mmol) and WSCI HC1 (0.91 g, 4.74 mmo 1) was sequentially added, and the mixture was stirred for 8 hours while gradually warming to room temperature.
- HOBt-H 2 O (0.61 g, 3.95 mmol
- N-methylmorpholine (1.73 mL, 15.7 mmol
- WSCI HC1 (0.91 g, 4.74 mmo 1
- Example 4 The title compound (1.62 g, 2.28 mmol) of Example 4 (4) was suspended in methylene chloride (1 OmL), and trifluoroacetic acid (10 mL) was added under ice cooling (internal temperature 5.C). ) was added, followed by stirring at room temperature for 3 hours. Ether was added to the reaction solution under ice-cooling, and the precipitate was collected by filtration to give the title compound (1.41 g, quantitative) as a white solid.
- Example 5 (1) 0—3-Sulfopropyl—D—Tyrosine V—Methylamide
- Example 4 Using the title compound of (1) in Example 4 and the title compound of (2) in Example 5, it was synthesized in the same manner as (4)-(7) of Example 4.
- Example 6 Using the title compound of Difficult Example 6 (1), it was synthesized in the same manner as in Example 1, (2).
- Example 6 (2) Using the title compound of Example 6 (2) and the title compound of Example 3 (2), it was synthesized in the same manner as in Example 1, (5)-(9).
- Example 6 Using the title compound of Example 6, (2) and the title compound of Example 1, (4), Synthesized by the same method as (5)-(9) in Example 1.
- Example 6 The title compound of Example 6, (2) was obtained by purification by column chromatography.
- the NMR data coincided with the NMR data of Example 4, (1) titled ⁇ 3 ⁇ 4.
- Example 8 (1) The title compound of Example 8 (1) and the title compound of Example 5 (2) were used and synthesized in the same manner as in Example 4, (4) -1 (7).
- Example 8 (1) and the title compound of Example 4 (3) were used and synthesized in the same manner as (4)-(7) of Example 4.
- the NMR data coincided with the NMR data of the title compound in Example 5, (3).
- N a- (tert-butoxycarbonyl) 1 (0-2-pentyloxyethyl) L-tyrosine N-methylamide A solution of the title compound (5.00 g, 16.99 mmol) in Example 1 (3) in THF (15 OmL) was added under ice-cooling to ethylene glycol monopentyl ether (7.76 g, 50 96mmo l), triphenylphosphine (1.37g 5 50.96mmo 1) and getyl azodicarboxylate (40% solution in toluene) (22.19g, 50.96mmo 1) are added sequentially, and at the same temperature for 2 hours. The mixture was stirred at room temperature for 68 hours.
- reaction solution was concentrated under i-phase, and purified by flash silica gel column chromatography (silica gel 150 g, hexane / ethyl acetate 5/1, 2/1, 1/1) to give the title as a white solid.
- Compound (7.86 g) was obtained.
- Example 10 (3) The title compound (4. llg, approx. 6. l lmmol) of Example 10 (3) was suspended in a solution consisting of ethanol (10 OmL)-water (5 OmL) and heated at 80 ° C to dissolve. Then, a solution prepared by dissolving sodium sulfite (0.85 g, 6.72 mmol) in water (5 OmL) was added to the solution, and the mixture was stirred under reflux for 22 hours. After cooling the reaction solution, ethanol was distilled off under reduced pressure, and the residue was washed with ethyl acetate (10 OmL). Give 56%): by concentrating under Ji added and the resulting blanking evening Nord to the aqueous layer (the 1. 65 g 5 Example 10 (3) 3 ⁇ 4 spoon ⁇ r) as a yellow solid 2 step yield from Was.
- Example 1 (2) (1.60 g, 4.1 l Ommol) and the title compound of Example 10 (5) (2.54 g, about 4.1 Ommo 1) were added to DMF (2 OmL).
- the dissolved solution under ice cooling, HOBt ⁇ ⁇ 2 0 (0. 63 g, 4. 10 mmo l), iV "- methylmorpholine (1. 8 OmL, 16. 4 Ommo 1) and WSCI 'HCl (0.94 g, 4.92 mmo 1) were added sequentially, and the mixture was stirred for 24.5 hours while gradually warming to room temperature.
- Example 1 The title compound (2.61 g, 3.75 mmol) of (6) in column 10 was suspended in trifluoroacetic acid (2 OmL) and stirred at room temperature for 4 hours. To the reaction solution was added ethyl ether (10 OmL), and the precipitate was collected by filtration to obtain the title compound (2.2 g, 95%) as a white solid.
- Example 10 To a solution of the title compound (2.20 g, 3.56 mmol) in Example 10 (7) dissolved in DMF (5 OmL) was added N-methylmorpholine (0.78 mL, 7.12 mmol) under ice-cooling. ), O-2-tetrahydropyran Vila sulfonyl hydroxyl ⁇ Min (0. 50 g, 4. 27mmo 1 ), ⁇ ⁇ ⁇ 2 ⁇ (0. 55 g, 3. 56 mmo 1) and WSCI ⁇ HC1 (0. 82 g 3 4. 27mmo 1) was added in sequence, and the mixture was stirred for 16 hours while gradually warming to room temperature.
- reaction solution was poured into an aqueous solution (20 OmL) in which sodium dihydrogen phosphate dihydrate (2.78 g, 17.81 mmo 1) was dissolved, and saturated with brine, and then THF-methanol (10/1)
- the mixture was extracted with a solution consisting of (200 mL x 1, 100 mL x 3), toluene was added to the extract, and the mixture was concentrated under reduced pressure. Getyl ether was added to the residue, and the precipitate was collected by filtration and dried to give the title ⁇ ) (4.50 g 5 quantitative) as a white solid. Obtained.
- Example 1 The title compound of (8) in Example 1 (4.50 g, about 3.56 mmol) was suspended in a solution consisting of water (2 OmL), methanol (40 mL) and THF (4 OmL), and the suspension was stirred at room temperature. 1N Hydrochloric acid (2 OmL) was added and stirred for 15 hours. From the reaction mixture, methanol and THF were distilled off under reduced pressure, and the residue was neutralized by adding water (30 OmL) and IN aqueous sodium hydrogen carbonate solution (2 OmL).
- Transfusion example 1 1 5-Methyl-3 (R)- ⁇ 1 (S) -Methylcarbamoyl-1- [4- (4-Sulfobutoxy) phenyl] ethylcarbamoyl ⁇ -2 (R or S) -Fuymidimidomethylhexano Hydroxamic acid sodium salt
- Example 12 (1) The title compound of Example 12 (1) was used and synthesized in the same manner as in Example 10 (4).
- Example 12 (2) The title compound of Example 12 (2) was used and synthesized in the same manner as in Example 10 (5).
- Example 1 (2) The title compound of Example 1 (2) and the title compound of Example 12 (3) were used and synthesized in the same manner as in Example 10, (6)-(9).
- Example 1 (1) Using the title compound of Example 1 (1) and 2-naphthylpromide, the compound was synthesized in the same manner as in Difficult Example 1 (2). However, purification was performed by flash column chromatography and recrystallization (hexane).
- Example 1 (2) The title compound of Example 1 (2) and the title compound of Example 14 (2) were used and synthesized in the same manner as in Example 1 (5)-(9).
- N- (tert-butoxycarbonyl) -L-phenylalanine (30.0 g, 113 mm 01) and benzyl alcohol (14. OmL, 136 mmo 1) were dissolved in methylene chloride (20 OmL) on a sickle.
- 4-dimethylaminopyridine (1.38 g, 11.3 mmo 1) and WSCI ⁇ HC1 (26.Og, 136 mmo 1) were sequentially added, and the mixture was stirred for 63 hours while gradually warming to room temperature. After the solvent was distilled off from the reaction solution, water (20 OmL) was added to the residue, and the mixture was extracted with ethyl acetate (40 OmL).
- the obtained extract was washed with 0.5N hydrochloric acid, water, a saturated aqueous solution of sodium hydrogen carbonate, water, and saturated food J »(20 OmL each), dried (anhydrous magnesium sulfate), and then dried under reduced pressure.
- the obtained residue was recrystallized from hexane to give the title compound (33.lg, 82%) as white crystals.
- the resulting precipitate is dissolved in ethyl acetate (30 OmL), washed successively with 0.5 N hydrochloric acid, water, a saturated aqueous solution of sodium hydrogen carbonate, water, and red water (10 OmL each), and dried (anhydrous). After magnesium sulfate), the mixture was concentrated under S. The obtained residue was recrystallized from ethyl acetate / hexane to give the ⁇ S compound (12.3 g, 76%) as white crystals.
- Example 15 The title compound (5) of Example 15 (11. 97g 3 17. 9mmol) and methanol (10 OML)-DMF was dissolved in a mixed solvent consisting of (15 OML), under ice-cooling, 10% palladium one-carbon catalyst ( After adding 1.20 g) and purging with hydrogen, the mixture was stirred at room temperature for 3.5 hours. After removing the catalyst from the reaction intense night by celite filtration, Concentrated under H. Water was added to the obtained residue, and the precipitate was collected by filtration, washed with water, and dried to give the title compound (9.17 g, 89%) as a white solid.
- the reaction solution was poured into an aqueous solution (40 OmL) in which sodium dihydrogen diphosphate monohydrate (7.79 g, 49.9 mmo 1) was dissolved, saturated with sodium chloride, and mixed with THF-methanol (10/1 ), Extracted (500 mL x 3), added to the extract, and concentrated under ME. Diisopropyl ether (1 L) was added to the residue, and the precipitate was collected by filtration and dried to give the title compound (37.80 g, constant) as a white solid.
- Example 15 The title compound of (7) in Example 15 (37.80 g, about 9.99 mmol 1) was suspended in a mixed solvent consisting of water (20 OmL) -methanol (40 OmL) -THF (20 OmL), and the mixture was suspended at room temperature. Under the atmosphere, 1N hydrochloric acid (20 OmL) was added, and the mixture was stirred at the same temperature for 8 hours. Methanol and THF were distilled off directly from the reaction solution, and the precipitate was collected by filtration and washed with isopropyl alcohol and diisopropyl ether. The obtained precipitate was suspended in water (250 mL) and neutralized with sodium hydrogen carbonate (0.84 g, 9.99 mMol).
- the resulting aqueous solution was purified using a synthetic adsorbent ram (Diaion HP-20: water, 50% aqueous methanol solution). The fractions eluted with 50% aqueous methanol intensely were collected and concentrated under ME until a precipitate appeared. Recrystallization of ZanKiyoshi water one I isopropyl alcohol, was obtained as a white crystalline title compound (1. 37g 3 22%).
- Example 16 The title compound (1.27 g, about 1.73 mm 01) of 28% de of Example 16 (1) was suspended in a solution consisting of water (25 mL) -methanol (6 OmL) -THF (2 OmL). Then, 1 ⁇ hydrochloric acid (1 OmL) was added at room temperature, and the mixture was stirred at the same temperature for 7 hours. Methanol and THF were distilled off from the reaction solution by reading, and water (2 OmL) and And sodium carbonate (1.00 g, 11.9 Ommo 1) was added for neutralization.
- the eluate in the latter half was collected, and methanol was distilled off under «] ⁇ and freeze-dried.
- the obtained freeze-dried product was precipitated from methanol-ethyl acetate to obtain Compound (0.24 g, 5 21%) as a white solid.
- Example 15 (6) Using the title compound of Example 15 (6) and taurine, difficult example 15 (7) — Synthesized by the same method as (8).
- Example 15 Using the title compound of Example 15 (6) and phosphorus, the compound was synthesized in the same manner as (1) and (2) of Example 16.
- Example 15 (6) Using the title compound of Example 15 (6) and the title compound of Example 22 (2), it was synthesized in the same manner as in Difficult Example 15 (7)-(8).
- Example 15 (6) Using the title compound of Example 15 (6) and sulfanilic acid, it was synthesized in the same manner as in Difficult Example 15 (7)-(8).
- Example 15 Using the title compound of (6) in Example 15 and sulfanilic acid, synthesis was carried out in the same manner as (1) and (2) of Example 16.
- Example 15 (3)-(6) Using the title compound of Difficult Example 13 (1) and the title compound (r) of Example 15 (2), it was synthesized in the same manner as in Example 15 (3)-(6).
- Example 25 Using the title compound of Example 25 (1) and aminomethanesulfonic acid, it was synthesized in the same manner as in Example 15, (7)-(8).
- a loopful of E. coli NIHJ JC-2 strain was inoculated into a test tube containing 5 mL of heart infusion broth (HIB) and cultured for about 24 hours.
- the cultured bacterial solution was washed three times by centrifugation (3000 rpm ⁇ 15 min, 20 ° C !, Tommy Seiko, RL-131) (1 OmL of fresh HIB medium was used for each wash). ).
- the washed cells were prepared so that about 107 colony forming units (CFU) ZML with fresh HI B medium was 0. 2 mL inoculated solution prepared to an Erlenmeyer flask containing fresh HIB medium 18.
- a final bacterial suspension concentration was adjusted to about 10 5 CFU / mL.
- 1 mL of a solution of the ⁇ conjugate prepared at a concentration of 2 mM was added (the final concentration of the compound was 100 zM).
- Shaking culture was performed at 37 ° C using a shaker (RGR-1 type, manufactured by Iwashiya Co., Ltd.), and 2 mL of the culture solution after 24 hours was sampled.
- the sampled culture solution was filtered (DISMIC, 0.45 m ⁇ Advantic Toyo), After dilution 10 5 times with sterile distilled water, Limulus reagent (LAL ES, Wako ⁇ ) to 200 / L was added, Tokishinome Isseki MT- 285 had been pre-heated to 37 ° C (Wako Pure Chemical) Was used to measure LPS concentration.
- the LPS inhibitory rate of the compound was calculated as a ratio of the LPS concentration of the compound added group to the LPS concentration of the compound added group. As a result, the suppression rate of the compound of Example 1 was 46.5 to 65.8%. Table 1 below shows the relative inhibition ratio of the compound of Example 1 as the inhibition ratio of the compound of Example 1.
- LPS concentrations in peritoneal and serum after dilution of the supernatant and serum collected PLF to 10 5 and 10 2-fold with it it it sterile distilled water, 200 ⁇ the rim Luz reagent (LAL ES, Wako Pure Chemical) L was added, and the measurement was performed using Toxinome overnight MT-285 (Wako), which had been heated to 37 ° C in advance.
- the amount of LPS per peritoneal cavity was calculated from the amount of collected peritoneal lavage fluid (PLF) X LPF concentration of LPS.
- the LPS inhibition rate of the compound was calculated as a ratio of the LPS concentration of the compound administration group to the LPS concentration of the physiological saline administration group.
- Table 2 shows the LPS suppression rate of each compound in blood and in blood.
- a tablet containing the following ingredients was produced by a conventional method.
- a capsule containing the following ingredients was produced by a conventional method.c Ingredients Per Capsule Difficult Compound 1 10 mg Lactose 165 mg Cornstarch 2 Omg Talc 5 mg Capsule weight 20 Omg
- Injection containing the following ingredients was manufactured by a conventional method.
- the hydroxamic acid-based sulfonic acid derivative and the pharmacologically acceptable salt thereof of the present invention have an LPS inhibitory effect, and include, for example, sepsis, MOF, rheumatoid arthritis, Clone disease, cachexia, myasthenia gravis It is useful for the prevention and treatment of diseases such as systemic lupus erythematosus, asthma, type I diabetes, psoriasis, other autoimmune diseases and inflammatory diseases.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001272761A AU2001272761A1 (en) | 2000-07-19 | 2001-07-19 | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
DE60129442T DE60129442T2 (de) | 2000-07-19 | 2001-07-19 | Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten |
KR1020037000808A KR100799192B1 (ko) | 2000-07-19 | 2001-07-19 | 히드록삼산계 설폰산 유도체 및 그의 의약 용도 |
CA002415954A CA2415954A1 (en) | 2000-07-19 | 2001-07-19 | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
EP01951935A EP1306367B1 (en) | 2000-07-19 | 2001-07-19 | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
US10/333,266 US6989401B2 (en) | 2000-07-19 | 2001-07-19 | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000219245 | 2000-07-19 | ||
JP2000219034 | 2000-07-19 | ||
JP2000-219034 | 2000-07-19 | ||
JP2000-219245 | 2000-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002006214A1 true WO2002006214A1 (fr) | 2002-01-24 |
Family
ID=26596313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/006275 WO2002006214A1 (fr) | 2000-07-19 | 2001-07-19 | Derives a l'acide sulfonique d'acides hydroxamiques et leur utilisation comme produits medicaux |
Country Status (9)
Country | Link |
---|---|
US (1) | US6989401B2 (ja) |
EP (1) | EP1306367B1 (ja) |
KR (1) | KR100799192B1 (ja) |
CN (1) | CN1215052C (ja) |
AT (1) | ATE367374T1 (ja) |
AU (1) | AU2001272761A1 (ja) |
CA (1) | CA2415954A1 (ja) |
DE (1) | DE60129442T2 (ja) |
WO (1) | WO2002006214A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004085396A1 (ja) * | 2003-03-26 | 2004-10-07 | Mitsubishi Pharma Corporation | 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法 |
WO2005037265A1 (ja) * | 2003-10-17 | 2005-04-28 | Mitsubishi Pharma Corporation | 併用薬剤 |
JP2010514674A (ja) * | 2006-10-12 | 2010-05-06 | ベラス ヘルス (インターナショナル) リミテッド | 3−アミノ−1−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体 |
US8574863B2 (en) | 2004-02-04 | 2013-11-05 | Pharmaaware Sepsis B.V. | Alkaline phosphatase for treating an inflammatory disease of the gastro-intestinal tract |
US9926544B2 (en) | 2014-01-24 | 2018-03-27 | Am-Pharma B.V. | Chimeric alkaline phosphatase-like proteins |
US10570380B2 (en) | 2014-01-24 | 2020-02-25 | Am-Pharma B.V. | Downstream processing of an alkaline phosphatase |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829085B2 (en) * | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
ES2412489T3 (es) | 2003-08-14 | 2013-07-11 | Thrombogenics N.V. | Anticuerpos contra el factor VIII con glucosilación modificada en la región variable |
JP2007515403A (ja) * | 2003-11-17 | 2007-06-14 | ワイス | N−置換フタルイミドの調製方法 |
WO2006085149A2 (en) | 2004-12-22 | 2006-08-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
WO2014015235A2 (en) * | 2012-07-20 | 2014-01-23 | Academia Sinica | 3,5,n-trihydroxy-alkanamide and derivatives: method for making same and use thereof |
CN116785450A (zh) * | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994010990A1 (en) * | 1992-11-13 | 1994-05-26 | British Biotech Pharmaceuticals Limited | Inhibition of tnf production |
EP0832875A1 (en) * | 1995-04-25 | 1998-04-01 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Highly water-soluble metalloproteinase inhibitor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
CA2058797A1 (en) * | 1991-02-01 | 1992-08-02 | Michael John Broadhurst | Amino acid derivatives |
GB9102635D0 (en) | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
US5318964A (en) | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
EP0689538B1 (en) | 1993-03-16 | 1998-08-12 | British Biotech Pharmaceuticals Limited | Hydroxamic acid derivatives as metalloproteinase inhibitors |
JPH07157470A (ja) | 1993-03-18 | 1995-06-20 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
CA2332946A1 (en) * | 1998-05-22 | 1999-12-02 | Welfide Corporation | Hydroxamic acid derivative and pharmaceutical use thereof |
US6797505B2 (en) * | 1998-05-27 | 2004-09-28 | Cell Genesys, Inc. | Recombinant AAV vectors for gene therapy of hemophilia A |
-
2001
- 2001-07-19 DE DE60129442T patent/DE60129442T2/de not_active Expired - Fee Related
- 2001-07-19 AU AU2001272761A patent/AU2001272761A1/en not_active Abandoned
- 2001-07-19 AT AT01951935T patent/ATE367374T1/de not_active IP Right Cessation
- 2001-07-19 CN CNB018130518A patent/CN1215052C/zh not_active Expired - Fee Related
- 2001-07-19 KR KR1020037000808A patent/KR100799192B1/ko not_active IP Right Cessation
- 2001-07-19 US US10/333,266 patent/US6989401B2/en not_active Expired - Fee Related
- 2001-07-19 WO PCT/JP2001/006275 patent/WO2002006214A1/ja active IP Right Grant
- 2001-07-19 EP EP01951935A patent/EP1306367B1/en not_active Expired - Lifetime
- 2001-07-19 CA CA002415954A patent/CA2415954A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994010990A1 (en) * | 1992-11-13 | 1994-05-26 | British Biotech Pharmaceuticals Limited | Inhibition of tnf production |
EP0832875A1 (en) * | 1995-04-25 | 1998-04-01 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Highly water-soluble metalloproteinase inhibitor |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004085396A1 (ja) * | 2003-03-26 | 2004-10-07 | Mitsubishi Pharma Corporation | 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法 |
WO2005037265A1 (ja) * | 2003-10-17 | 2005-04-28 | Mitsubishi Pharma Corporation | 併用薬剤 |
US8735087B2 (en) | 2004-02-04 | 2014-05-27 | Pharmaaware Sepsis B.V. | Use of alkaline phosphatase for preventing or reducing liver disease |
US8574863B2 (en) | 2004-02-04 | 2013-11-05 | Pharmaaware Sepsis B.V. | Alkaline phosphatase for treating an inflammatory disease of the gastro-intestinal tract |
JP2015007047A (ja) * | 2006-10-12 | 2015-01-15 | ビーエイチアイ リミテッド パートナーシップ | 3−アミノ−1−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体 |
US8748656B2 (en) | 2006-10-12 | 2014-06-10 | Bhi Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
JP2010514674A (ja) * | 2006-10-12 | 2010-05-06 | ベラス ヘルス (インターナショナル) リミテッド | 3−アミノ−1−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体 |
US9499480B2 (en) | 2006-10-12 | 2016-11-22 | Bhi Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US10238611B2 (en) | 2006-10-12 | 2019-03-26 | Bellus Health Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US10857109B2 (en) | 2006-10-12 | 2020-12-08 | Bellus Health, Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US11020360B2 (en) | 2006-10-12 | 2021-06-01 | Bellus Health Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US9926544B2 (en) | 2014-01-24 | 2018-03-27 | Am-Pharma B.V. | Chimeric alkaline phosphatase-like proteins |
US10570380B2 (en) | 2014-01-24 | 2020-02-25 | Am-Pharma B.V. | Downstream processing of an alkaline phosphatase |
US10822597B2 (en) | 2014-01-24 | 2020-11-03 | Am-Pharma B.V. | Chimeric alkaline phosphatase-like proteins |
US11746340B2 (en) | 2014-01-24 | 2023-09-05 | Am-Pharma B.V. | Chimeric alkaline phosphatase-like proteins |
Also Published As
Publication number | Publication date |
---|---|
DE60129442T2 (de) | 2008-04-17 |
AU2001272761A1 (en) | 2002-01-30 |
CN1443158A (zh) | 2003-09-17 |
EP1306367A1 (en) | 2003-05-02 |
KR20030029628A (ko) | 2003-04-14 |
ATE367374T1 (de) | 2007-08-15 |
CN1215052C (zh) | 2005-08-17 |
US6989401B2 (en) | 2006-01-24 |
DE60129442D1 (de) | 2007-08-30 |
CA2415954A1 (en) | 2003-01-17 |
KR100799192B1 (ko) | 2008-01-31 |
EP1306367A4 (en) | 2004-06-09 |
US20030176486A1 (en) | 2003-09-18 |
EP1306367B1 (en) | 2007-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69130408T2 (de) | Endothelinantagonistische Peptidderivate | |
JP3827324B2 (ja) | 金属タンパク質分解酵素阻害剤 | |
JPH1160551A (ja) | スルホニルアミノカルボン酸 | |
WO2002006214A1 (fr) | Derives a l'acide sulfonique d'acides hydroxamiques et leur utilisation comme produits medicaux | |
US9150505B2 (en) | Prophylactic or therapeutic agent for diabetes or obesity | |
JPH08508027A (ja) | 金属タンパク加水分解酵素阻害剤である天然アミノ酸誘導体 | |
EP2252596A1 (en) | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | |
AU2017326611A1 (en) | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | |
JP2018526448A (ja) | 一酸化窒素を放出可能なプロドラッグ分子 | |
WO2000007985A1 (fr) | Nouveaux derives d'uree renfermant des heterocycles aromatiques azotes | |
CN104662004A (zh) | 新型瑞巴派特前药、其制备方法及用途 | |
JP2003505367A (ja) | マトリックスメタロプロテイナーゼ阻害剤としての3−アリールスルホニル−2−(置換メチル)プロパン酸誘導体 | |
JPH0154349B2 (ja) | ||
WO1996030354A1 (fr) | Derives d'acide epoxysuccinique | |
RU2017748C1 (ru) | Производные нитратоалкановых кислот или их фармацевтически приемлемые соли | |
EP0723974B1 (fr) | Dérivés de mercaptoalcanoyldipeptides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
RU2631320C2 (ru) | Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты | |
TW200920352A (en) | New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them | |
WO2000004001A1 (fr) | Piperazinones substituees et leurs applications en therapeutique | |
WO2024096066A1 (ja) | 中枢神経系損傷疾患を処置または予防するための環状ペプチド誘導体組成物 | |
WO1999040063A1 (fr) | Nouveaux derives de l'acide hydroxamique de type azapeptide | |
HUT51291A (en) | Process for production of new derivatives of dipeptide with inhibitor effect | |
JPS58116471A (ja) | 4−ヒドロキシメチル−1−フタラゾンエステル誘導体およびその塩 | |
KR100965247B1 (ko) | 신규한 아릴설포닐이미다졸론 유도체 화합물 및 그화합물을 함유한 항암제 조성물 | |
WO1999067235A1 (fr) | Composes cycliques a cinq elements |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 512120 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2415954 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037000808 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037000839 Country of ref document: KR Ref document number: 018130518 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001951935 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001272761 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10333266 Country of ref document: US |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020037000839 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020037000839 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037000808 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001951935 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Country of ref document: RU Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Country of ref document: RU Kind code of ref document: A Format of ref document f/p: F |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001951935 Country of ref document: EP |